The comprehensive study, led by Dr. Brett Loman of the Department of Animal Sciences and Division of Nutritional Sciences, scoured close to 16,000 published studies to isolate the highest-quality data concerning nutrition’s role in mitigating GI side effects during cancer therapy. This monumental effort distilled the literature down to 139 rigorous studies, encompassing over 10,000 patients. By applying sophisticated meta-analytic techniques, the research team conducted more than 150 analyses to evaluate various nutritional approaches, including nutrient supplementation, dietary counseling, and oral nutritional supplements.

Nutrition therapy is a foundational adjunct to cancer treatment, primarily used to prevent weight loss and support the immune system. However, the existing literature has seldom focused specifically on the alleviation of GI symptoms caused by chemotherapy, radiation, or targeted therapies. This gap in research inspired the Illinois team to mine ancillary data within broader nutrition studies to uncover evidence-based strategies to directly combat GI side effects. Their findings hold promise for reshaping therapeutic nutrition to become more symptom-targeted.

Their meta-analysis revealed that nutrient supplementation emerged as the most potent and consistent approach for reducing the incidence and severity of nausea, vomiting, and diarrhea among cancer patients. This category encompassed an array of bioactive nutrients, such as specific amino acids—including glutamine—probiotics, prebiotics, synbiotics, essential fatty acids like omega-3s, as well as herbs and minerals, notably ginger and zinc. Intriguingly, these nutrients exerted cancer-specific and symptom-specific efficacy. For example, probiotics demonstrated a significant reduction in diarrhea incidence among colorectal cancer patients, illuminating a nuanced and personalized nutritional pathway for clinical application.

Dietary counseling also showed tangible benefits in ameliorating GI disturbances. One-on-one sessions between dietitians and patients, focusing on dietary habits and inflammation management, were linked to decreases in diarrhea, constipation, nausea, anorexia, and vomiting. Nevertheless, the heterogeneity and personalized nature of counseling interventions complicated granular analysis of which specific practices were most efficacious. However, by integrating the nutrient-specific insights uncovered in the meta-analysis, dietitians could refine their guidance with targeted nutritional recommendations, thereby elevating their role as frontline implementers of symptom-specific therapy.

In marked contrast, findings regarding oral nutritional supplements—commonly nutritionally complete meal replacer drinks—were less encouraging in the context of GI symptom management. Although these supplements provided essential macro- and micronutrients, the analysis showed no statistically significant benefits in reducing GI distress symptoms. Equally important, they did not exacerbate symptoms, offering a neutral effect. This suggests that while current formulations meet general nutritional requirements, they lack the targeted bioactives necessary to mitigate GI side effects effectively.

Dr. Loman and his team posit that future formulation of oral nutritional supplements enriched with proven bioactive compounds—such as ginger, probiotics, or amino acids—could deliver both complete nutrition and therapeutic relief from GI symptoms. This dual-purpose approach is expected to enhance patient adherence to cancer therapies by improving tolerance. The research lays the groundwork for subsequent preclinical and clinical trials designed to test these optimized formulations rigorously.

This meta-analysis stands as a critical milestone in the evolving field of nutritional oncology, illuminating how integrating robust nutrition science with personalized cancer care can tangibly improve patient outcomes beyond tumor control alone. By cataloging and analyzing data from an unparalleled volume of studies, the work advances a precision nutrition paradigm that aligns symptom management strategies with cancer type and treatment modality.

The study’s publication in Advances in Nutrition marks a significant contribution to both clinical nutrition and oncology research. Funded partly by USDA’s National Institute of Food and Agriculture and supported by Illinois’ Division of Nutritional Sciences, the research underscores the vital intersection of agriculture, nutrition science, and medical innovation. Collaborative affiliations with initiatives in personalized nutrition and microbial systems further amplify the research’s translational potential.

In sum, the meta-analysis by Drs. Loman and Alzoubi reveals that nutrient supplementation—particularly with targeted amino acids, probiotics, and anti-inflammatory compounds—holds the most promise for alleviating debilitating GI side effects in cancer patients. Personalized dietary counseling complements this by tailoring interventions to individual needs, while current oral nutritional supplements require reformulation to incorporate bioactive nutrients actively. This research provides a vibrant blueprint for clinicians and dietitians to enhance cancer therapy tolerability through evidence-based nutritional strategies.

As cancer survivorship grows, addressing the quality of life during treatment is paramount. These findings open new avenues where interdisciplinary efforts in nutrition science, oncology, and patient care converge to refine the supportive therapies integral to cancer management. The vision articulated by the Illinois researchers to develop symptom-specific nutritional regimens heralds a new chapter in improving patient experiences and outcomes in oncology. Their ongoing and future studies promise to translate these meta-analytic insights into tangible, everyday interventions that empower patients to better withstand the rigors of cancer therapy.

Subject of Research: Nutritional interventions to mitigate gastrointestinal side effects during cancer therapy
Article Title: Nutrition Interventions in the Treatment of Gastrointestinal Symptoms during Cancer Therapy: A Systematic Review and Meta-analysis
Web References: https://www.sciencedirect.com/science/article/pii/S2161831325001218
References: 10.1016/j.advnut.2025.100485
Image Credits: University of Illinois Urbana-Champaign
Keywords: Cancer therapy, gastrointestinal side effects, nutrition therapy, nutrient supplementation, probiotics, amino acids, dietary counseling, meta-analysis, chemotherapy, radiation, nutritional oncology

A prominent presentation will focus on the INCIPIENT trial, an avant-garde phase I clinical study investigating CAR T-cell therapy engineered to combat recurrent glioblastoma (GBM). GBM remains one of the most aggressive and heterogeneous brain tumors, presenting considerable obstacles due to its complex antigenic landscape. To surmount these challenges, investigators developed a dual-action CAR T-cell product, termed CARv3-TEAM-E, which not only targets the EGFRvIII mutation predominant in GBM but also secretes T-cell Engaging Antibody Molecules (TEAMs) directed at wild-type EGFR. This dual-targeting approach is designed to broaden the immune attack on tumor heterogeneity, potentially improving therapeutic efficacy.

Initial findings from the INCIPIENT study indicate that intraventricular delivery of CARv3-TEAM-E cells results in sustained presence of CAR T cells within the cerebrospinal fluid (CSF) for a mean duration exceeding one month. The immunological milieu within the CSF revealed dynamic fluctuations, with an immediate influx of granulocytes, natural killer cells, B cells, and monocytes post-infusion that gradually subsided over several weeks. These data provide crucial insights into the local immune dynamics elicited by CAR T-cell therapy in the central nervous system and underscore the potential for modulating the tumor microenvironment.

Complementing these immunological studies, the phase I safety assessment of CARv3-TEAM-E demonstrated successful manufacturing of CAR T cells for all enrolled patients and tolerable safety profiles following lymphodepleting chemotherapy regimens. Patients received up to six intraventricular doses via Ommaya catheter after preconditioning with fludarabine and cyclophosphamide, indicating feasible delivery strategies for maximizing local immune engagement while managing toxicity. This safety and feasibility evidence forms a foundational step towards expanding CAR T therapeutics for GBM—a domain historically marked by limited treatment options.

Beyond oncologic immunotherapy, the Mass General Brigham team unveiled an innovative psychosocial digital application aimed at transforming supportive care for caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT). Recognizing that caregivers endure significant psychological distress and quality of life impairments, the BMT-CARE App was designed as a scalable, self-guided intervention to address these unmet needs. A rigorously conducted randomized controlled trial demonstrated that engagement with this app yielded statistically significant improvements in caregiver quality of life, coping strategies, and reductions in depression and post-traumatic stress symptoms, representing a promising digital health advancement in oncology supportive care.

In addressing another pressing clinical challenge, investigators led by Dr. Ayal A. Aizer from Brigham and Women’s Hospital presented findings from a multicenter phase 3 randomized trial evaluating stereotactic radiation (SRS/SRT) versus hippocampal avoidance whole brain radiation (HA-WBRT) in patients harboring multiple brain metastases. Prior studies had established SRS as superior for patients with four or fewer lesions, but evidence in cases with 5 to 20 metastases was lacking. This trial compellingly demonstrated that SRS/SRT not only reduced symptom severity and improved functional outcomes compared to HA-WBRT but did so without compromising overall survival, advocating for revision of current radiotherapeutic standards in patients with multiple brain metastases.

Moving into gynecologic oncology, a phase II study led by Dr. Oladapo O. Yeku explored the therapeutic synergy of cisplatin-sensitized radiation therapy combined with pembrolizumab in patients with unresectable vulvar cancer—a malignancy that disproportionately affects underserved patient populations and has witnessed rising incidence and mortality. This single-arm trial enrolled primarily patients with primary unresectable disease and revealed promising improvements in overall response rates and six-month recurrence-free survival, heralding potential new frontline strategies via combination immunotherapy and chemoradiation.

In the realm of cutaneous malignancies, frontline research presented by Dr. Meghan Mooradian detailed a randomized phase II investigation comparing neoadjuvant anti-PD-1 therapy alone versus combined anti-PD-1 and anti-TIM-3 blockade in high-risk resectable melanoma. Although specifics remain embargoed until the conference date, this study highlights the cutting-edge exploration of checkpoint inhibitor combinations designed to overcome therapeutic resistance and improve pathological response rates prior to surgical intervention.

Collectively, the array of presentations from Mass General Brigham at ASCO 2025 underscores a multifaceted approach to cancer research, encompassing sophisticated immunotherapies exploiting tumor heterogeneity, precision radiation techniques optimizing neurocognitive preservation, and digital tools enhancing caregiver support. Such integrative efforts reflect the institution’s commitment to advancing cancer care through innovation not only in tumor-directed treatments but encompassing patient and family-centered interventions.

With rapidly evolving therapeutic landscapes, these investigational studies demonstrate how next-generation strategies can address long-standing barriers to effective cancer management. The dual-antigen targeting CAR T cells for GBM represent a paradigm shift in immunotherapy deployment within the central nervous system, overcoming antigen escape and tumor heterogeneity. Meanwhile, the positive psychosocial outcomes associated with the BMT-CARE App herald a transformative leap in digitizing oncology support services, potentiating scalability and personalization.

Similarly, the phase 3 radiation trial offers a compelling evidence base to expand the application of SRS to patients traditionally relegated to whole brain radiation, potentially redefining standards of care with tangible quality of life benefits. In vulvar cancer, the integration of immune checkpoint blockade with chemoradiation opens avenues toward improved survival in an underserved malignancy, while neoadjuvant checkpoint combinations in melanoma continue to refine the oncology precision toolkit.

As the field moves towards individualized, multi-dimensional cancer management, the forthcoming detailed data and peer-reviewed publications will be essential in translating these clinical findings into practice. The ASCO Annual Meeting will provide an invaluable forum for dissemination, discussion, and collaborative advancement, affirming Mass General Brigham’s pivotal role in shaping the future of oncology research and patient care.

Subject of Research: Innovative cancer therapies and supportive care strategies presented by Mass General Brigham researchers at ASCO 2025, including CAR T-cell therapy for glioblastoma, radiation treatment for brain metastases, immunotherapy for vulvar cancer and melanoma, and digital psychosocial interventions for hematopoietic stem cell transplant caregivers.

Article Title: Mass General Brigham Unveils Breakthroughs in Oncology at ASCO 2025: From Dual-Targeted CAR T-Cells to Digital Caregiver Support

News Publication Date: Not specified (to coincide with ASCO 2025, May 30 – June 3, 2025)

Web References:

• https://meetings.asco.org/2025-asco-annual-meeting
• https://www.massgeneralbrigham.org

Keywords: Cancer research, CAR T-cell therapy, glioblastoma, brain metastases, stereotactic radiation, hematopoietic stem cell transplantation, psychosocial digital application, vulvar cancer, immunotherapy, melanoma, clinical trials, oncology innovation